CLINICAL_TRIALS
trial_result
· 2023-09-14
Clinical Trial Update: A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid [Phase 2]
Summary
A Phase 2 trial of adjunctive AKST4290 for bullous pemphigoid was terminated; results posted in 2023.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Alkahest, Inc. | Conditions: Pemphigoid, Bullous | Phase 2 | Status: TERMINATED | Results posted: 2023-09-14